AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Johnson & Johnson recently announced results of a study concerning the effectiveness of Regranex (Becaplermin) Gel in the treatment of diabetic foot ulcers. Regranex (Becaplermin) gel 0.01% is a recombinant human platelet-derived growth factor (rhPDGF). The results were based on a retrospective cohort study that included 24,000 patients with neuropathic diabetic foot ulcers, treated at wound clinics between 1998 and 2004. All data was gathered from a claims database. The study compared diabetic foot ulcers treated with rhPDGF and those that ...